Skip to main content
Evidence Snapshot

Oxytocin receptor

CHEMBL2049 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2049
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Oxytocin receptor as ChEMBL target CHEMBL2049, mapped to UniProt P30559. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Oxytocin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2049
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30559
Oxytocin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Oxytocin receptor matters

As of 2026-09-13

Oxytocin receptor is reviewed as Oxytocin receptor (UniProt P30559); Oxytocin receptor shows approved-linked disease relevance led by premature birth. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 11 approved drugs, 1335 compounds, and 247 assays, with lead potency reaching pChEMBL 11.0.

Disease context
premature birth

Oxytocin receptor shows approved-linked disease relevance led by premature birth. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ATOSIBAN, ATOSIBAN ACETATE, FE 202767.

Start review with premature birth because it currently carries approved-linked support. Linked drugs include ATOSIBAN, ATOSIBAN ACETATE, FE 202767, NOLASIBAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 5 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 1335 compounds, and 247 assays for this target. The dominant activity type is KI. CHEMBL395429 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL395429 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Oxytocin receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30559, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why premature birth is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1335
Total Compounds
247
Total Assays
11
Approved Drugs
IC50: 268.0, KI: 826.0, EC50: 555.0, KD: 37.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL395429
 11.0 EC50 Approved
No preferred name
CHEMBL3353930
 11.0 EC50 —
No preferred name
CHEMBL3353932
 11.0 EC50 —
No preferred name
CHEMBL3353939
 11.0 EC50 —
No preferred name
CHEMBL3353940
 11.0 EC50 —

Approved Drugs

Structure Compound First Approval
VASOPRESSIN
CHEMBL373742
 2014
MOZAVAPTAN
CHEMBL420762
 2006
ATOSIBAN
CHEMBL382301
 2000
OXYTOCIN
CHEMBL395429
 1980
DESMOPRESSIN
CHEMBL1429
 1978
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2049